OncoSil Medical (ASX:OSL) - Share price, News & Analysis

OSL fundamental analysis
Snowflake Score
Valuation	0/6
Future Growth	1/6
Past Performance	0/6
Financial Health	4/6
Dividends	0/6

OSL Stock Overview

OncoSil Medical Limited, a medical device company, focuses on the development and commercialization of localized radiation therapy for the treatment of pancreatic and bile duct cancer in Australia.

Rewards

Revenue is forecast to grow 6.86% per year

Risk Analysis

Earnings are forecast to decline by an average of 6.3% per year for the next 3 years

Has less than 1 year of cash runway

Highly volatile share price over the past 3 months

Makes less than USD$1m in revenue (A$1M)

+ 3 more risks

OncoSil Medical Competitors

Cryosite

ASX:CTE

AU$31.7m

BPH Energy

ASX:BPH

AU$7.6m

Proteomics International Laboratories

ASX:PIQ

AU$84.6m

EZZ Life Science Holdings

ASX:EZZ

AU$12.6m

Price History & Performance

Summary of all time highs, changes and price drops for OncoSil Medical
Historical stock prices
Current Share Price	AU$0.036
52 Week High	AU$0.081
52 Week Low	AU$0.033
Beta	-0.050
1 Month Change	-33.33%
3 Month Change	-7.69%
1 Year Change	-36.84%
3 Year Change	-34.54%
5 Year Change	-64.00%
Change since IPO	-82.00%

Recent News & Updates

May 24

Companies Like OncoSil Medical (ASX:OSL) Could Be Quite Risky

We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...

Shareholder Returns

	OSL	AU Life Sciences	AU Market
7D	-16.3%	-5.3%	1.4%
1Y	-36.8%	-43.4%	-11.3%

Return vs Industry: OSL exceeded the Australian Life Sciences industry which returned -43.4% over the past year.

Return vs Market: OSL underperformed the Australian Market which returned -11.3% over the past year.

Price Volatility

Is OSL's price volatile compared to industry and market?
OSL volatility
OSL Average Weekly Movement	24.3%
Life Sciences Industry Average Movement	15.5%
Market Average Movement	9.7%
10% most volatile stocks in AU Market	16.3%
10% least volatile stocks in AU Market	4.2%

Stable Share Price: OSL is more volatile than 90% of Australian stocks over the past 3 months, typically moving +/- 24% a week.

Volatility Over Time: OSL's weekly volatility has increased from 14% to 24% over the past year.

About the Company

Founded	Employees	CEO	Website
2005	n/a	Nigel Lange	https://www.oncosil.com.au

OncoSil Medical Limited, a medical device company, focuses on the development and commercialization of localized radiation therapy for the treatment of pancreatic and bile duct cancer in Australia. Its lead product is OncoSil, a brachytherapy device indicated for the treatment of patients with locally advanced unresectable pancreatic cancer, in combination with gemcitabine-based chemotherapy. The company was formerly known as NeuroDiscovery Limited and changed its name to OncoSil Medical Limited in May 2013.

OncoSil Medical Fundamentals Summary

How do OncoSil Medical's earnings and revenue compare to its market cap?
OSL fundamental statistics
Market Cap	AU$35.68m
Earnings (TTM)	-AU$11.38m
Revenue (TTM)	AU$1.29m

27.9x

P/S Ratio

-3.1x

P/E Ratio

Is OSL overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report
OSL income statement (TTM)
Revenue	AU$1.29m
Cost of Revenue	AU$1.27m
Gross Profit	AU$19.84k
Other Expenses	AU$11.40m
Earnings	-AU$11.38m

Last Reported Earnings

Dec 31, 2021

Next Earnings Date

n/a

Earnings per share (EPS)	-0.011
Gross Margin	1.54%
Net Profit Margin	-884.84%
Debt/Equity Ratio	0%

How did OSL perform over the long term?

See historical performance and comparison

We’ve recently updated our valuation analysis.

Valuation

Is OSL undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Below Fair Value
Significantly Below Fair Value
PEG Ratio

Key Valuation Metric

Which metric is best to use when looking at relative valuation for OSL?

Other financial metrics that can be useful for relative valuation.

The above table shows the n/a ratio for OSL. This is calculated by dividing OSL's market cap by their current preferred multiple.
What is OSL's n/a Ratio?
n/a Ratio	0x
n/a	n/a
Market Cap	AU$35.68m

OSL key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	22.9x
Enterprise Value/EBITDA	-2.6x
PEG Ratio	n/a

Price to Sales Ratio vs Peers

How does OSL's PS Ratio compare to its peers?

OSL PS Ratio vs Peers

The above table shows the PS ratio for OSL vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	PS	Estimated Growth	Market Cap
Peer Average	22.9x
CTE Cryosite	2.9x	n/a	AU$31.7m
BPH BPH Energy	57.5x	n/a	AU$7.6m
PIQ Proteomics International Laboratories	30.4x	n/a	AU$84.6m
EZZ EZZ Life Science Holdings	0.8x	n/a	AU$12.6m
OSL OncoSil Medical	27.9x	6.9%	AU$35.7m

Forward PS

Price-To-Sales vs Peers: OSL is expensive based on its Price-To-Sales Ratio (27.9x) compared to the peer average (22.9x).

Price to Earnings Ratio vs Industry

How does OSL's PE Ratio compare vs other companies in the Global Life Sciences Industry?

Price-To-Sales vs Industry: OSL is expensive based on its Price-To-Sales Ratio (27.9x) compared to the Global Life Sciences industry average (5.3x)

Price to Sales Ratio vs Fair Ratio

What is OSL's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

OSL PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio	27.9x
Fair PS Ratio	3.5x

Price-To-Sales vs Fair Ratio: OSL is expensive based on its Price-To-Sales Ratio (27.9x) compared to the estimated Fair Price-To-Sales Ratio (3.5x).

Share Price vs Fair Value

What is the Fair Price of OSL when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate OSL's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate OSL's fair value for valuation analysis.

Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate OSL's PEG Ratio to determine if it is good value.

Discover undervalued companies

Future Growth

How is OncoSil Medical forecast to perform in the next 1 to 3 years based on estimates from 1 analyst?

Future Growth Score

1/6

Future Growth Score 1/6

Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Future ROE

-6.3%

Forecasted annual earnings growth

Earnings and Revenue Growth Forecasts

Analyst Future Growth Forecasts

Earnings vs Savings Rate: OSL is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: OSL is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: OSL is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: OSL's revenue (6.9% per year) is forecast to grow faster than the Australian market (5.2% per year).

High Growth Revenue: OSL's revenue (6.9% per year) is forecast to grow slower than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: OSL is forecast to be unprofitable in 3 years.

Discover growth companies

Past Performance

How has OncoSil Medical performed over the past 5 years?

Past Performance Score

0/6

Past Performance Score 0/6

Quality Earnings
Growing Profit Margin
Earnings Trend
Accelerating Growth
Earnings vs Industry
High ROE

-3.6%

Historical annual earnings growth

Earnings and Revenue History

Quality Earnings: OSL is currently unprofitable.

Growing Profit Margin: OSL is currently unprofitable.

Past Earnings Growth Analysis

Earnings Trend: OSL is unprofitable, and losses have increased over the past 5 years at a rate of 3.6% per year.

Accelerating Growth: Unable to compare OSL's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: OSL is unprofitable, making it difficult to compare its past year earnings growth to the Life Sciences industry (34.5%).

Return on Equity

High ROE: OSL has a negative Return on Equity (-180.83%), as it is currently unprofitable.

Discover strong past performing companies

Financial Health

How is OncoSil Medical's financial position?

Financial Health Score

4/6

Financial Health Score 4/6

Short Term Liabilities
Long Term Liabilities
Debt Level
Reducing Debt
Stable Cash Runway
Forecast Cash Runway

Financial Position Analysis

Short Term Liabilities: OSL's short term assets (A$7.5M) exceed its short term liabilities (A$1.4M).

Long Term Liabilities: OSL's short term assets (A$7.5M) exceed its long term liabilities (A$234.2K).

Debt to Equity History and Analysis

Debt Level: OSL is debt free.

Reducing Debt: OSL had no debt 5 years ago.

Balance Sheet

Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: OSL has less than a year of cash runway based on its current free cash flow.

Forecast Cash Runway: OSL has less than a year of cash runway if free cash flow continues to reduce at historical rates of 12.3% each year

Discover healthy companies

Dividend

What is OncoSil Medical current dividend yield, its reliability and sustainability?

Dividend Score

0/6

Dividend Score 0/6

Notable Dividend
High Dividend
Stable Dividend
Growing Dividend
Earnings Coverage
Future Dividend Coverage

Dividend Yield vs Market

Notable Dividend: Unable to evaluate OSL's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate OSL's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.

Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if OSL's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if OSL's dividend payments have been increasing.

Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.

Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as OSL has not reported any payouts.

Discover strong dividend paying companies

Management

How experienced are the management team and are they aligned to shareholders interests?

1.8yrs

Average management tenure

CEO

Nigel Lange

1.42yrs

Tenure

AU$963,672

Compensation

Mr. Nigel Lange serves as Chief Executive officer, Managing Director and Director of OncoSil Medical Limited since January 21, 2021. He served as President of EMEA at OncoSil Medical Limited since May 2020...

CEO Compensation Analysis

Compensation vs Market: Nigel's total compensation ($USD669.77K) is above average for companies of similar size in the Australian market ($USD288.24K).

Compensation vs Earnings: Insufficient data to compare Nigel's compensation with company performance.

Leadership Team

Experienced Management: OSL's management team is not considered experienced ( 1.8 years average tenure), which suggests a new team.

Board Members

Experienced Board: OSL's board of directors are not considered experienced ( 1.4 years average tenure), which suggests a new board.

Ownership

Who are the major shareholders and have insiders been buying or selling?

Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.

Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 24.3%.

Data	Last Updated (UTC time)
Company Analysis	2022/06/27 00:00
End of Day Share Price	2022/06/27 00:00
Earnings	2021/12/31
Annual Earnings	2021/06/30